PRoFESS® - Conclusions of the antiplatelet arm

• PRoFESS® was not able to meet the pre-specified non-inferiority criteria for ER-DP + ASA vs. clopidogrel
• ER-DP + ASA and clopidogrel had similar rates of recurrent stroke and major vascular events
• The composite outcome of stroke, MI or vascular death rates were identical in the two groups
• The major haemorrhagic complication rates were not significantly different between ER-DP + ASA and clopidogrel. Recurrent ischaemic strokes (the most common event after stroke) were numerically less frequent in the Aggrenox® group (7.7 % vs. 7.9 %, statistically not significant), while haemorrhagic strokes were more common (0.9 % vs. 0.5 %, p<0.01).
• There was no significant difference in the risk of fatal or disabling stroke
• Net benefit/ risks were similar in the 2 agents defined as the combination of recurrent stroke and major haemorrhage

If you would like to learn more about PRoFESS® and the results of this study or Aggrenox® in general please follow the link to the Aggrenox® Slide Kit or the link to the homepage of the New England Journal of Medicine for the online publication & the editorial: (Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke)